Immunotherapy induced hypothyroidism with hyperlipidemia: a case report and literature review

Abstract

In recent years, immune checkpoint inhibitors have been increasingly used in clinical practice. While considering the efficacy of immunotherapy, it is also necessary to be alert to immune-related adverse effects (irAEs). These include skin, gastrointestinal, liver, endocrine, and pulmonary toxicities. Here, we report a case of irAEs of hypothyroidism with marked hyperlipidemia during sintilimab administration.